Update on clinical guideline communication in October 2018 provider newsletter

We’d like to make two corrections on information we provided in the October 2018 issue of our provider newsletter. In the article titled ‘Clinical guideline updates are available on anthem.com’, we incorrectly advised that the following guidelines previously unadopted would become effective January 1, 2019.

 

CG-DRUG-33 - Palonosetron

CG-DRUG-40 - Bortezomib (Velcade®)

CG-DRUG-52 - Temsirolimus (Torisel®)

CG-DRUG-60 - Gonadotropin Releasing Hormone Analogs for Oncologic Indications

 

Please be advised that these guidelines will remain unadopted at this time and will not become effective in January.

 

In addition, in the same article we announced that the guideline CG-DRUG-44 - Pegloticase (Krystexxa®) would also become effective on January 1, 2019.  In fact, guideline CG-DRUG-44 became effective on September 1, 2018, as we communicated in the June 2018 issue of our provider newsletter. 

 

We apologize for any inconvenience.